Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management

Inclusion Criteria: * Age 18 and more * Index event of non-ST or ST segment elevation ACS * Provision of signed informed consent Exclusion Criteria: * Hypersensitivity to aspirin or ticagrelor * Oral anticoagulation therapy that cannot be stopped * Treated with thrombolysis within 24hrs * Any other reason the investigator deems the subject to be unsuitable for the study e.g., Active malignant tumor * Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers * Any life-threatening condition with life expectancy less than 6months * Mental condition (dementia, alcohol or drug abuse) which may be affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study * High risk due to malignant hypertension * The conditions associated with increased risk of bradycardiac events * Subjects with severe liver disease * Subjects requiring dialysis * Increased bleeding risk * History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days * Thrombocytopenia or leukopenia * Positive pregnancy test or is known to be pregnant